



Access to Data A Drug Bulletins' Perspective



Teresa Leonardo Alves

HAI Europe Open Seminar
12 October 2012


Access to data

- 1. Essential to our work**
- 2. Enables public scrutiny**
- 3. Encourages accountability**

There is more than meets the eye...




All that glitters...is not gold!



Transparency?

The Swedish agency report on rimonabant – supplied in 2009 by EMA



Only 3/68
pages
were legible

Information ratings in response to our systematic requests (I)



- Company provided detailed information including unpublished data and packaging items.



- Company provided information limited to administrative and published data.



- Company provided minimal information, mainly administrative data.



- Company provided no information.

Information ratings in response to our systematic requests (II)

The revised T-scores will be as follows:

- manufacturer provided complete clinical evaluation
- manufacturer provided additional useful information
- manufacturer provided the AusPAR and/or the product information
- manufacturer declined to supply data
- manufacturer did not respond to request for data

- Australian Prescriber is a free, independent publication providing readily accessible information about drugs and therapeutics, published by the National Prescribing Service.
- Transparency T-test rates companies' willingness to provide clinical information about new drugs
- Published every 2 years

Prescrire's Information Prizes



- Awarded annually
- **Information Awards:** focus on the quality of the information provided by pharmaceutical companies about products that were examined by the New Products section of our French edition during a given year
- **Red lanterns:** for companies that either fail to reply to our information requests, or respond too late, or provide insufficient data.